129 related articles for article (PubMed ID: 38194244)
21. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
22. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
[TBL] [Abstract][Full Text] [Related]
24. Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic Depression.
Souza-Marques B; Telles M; Leal GC; Faria-Guimarães D; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Souza L; Lins-Silva D; Mello RP; Guerreiro-Costa L; Bandeira ID; Lacerda ALT; Sampaio AS; Quarantini LC
J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):408-412. PubMed ID: 35727083
[TBL] [Abstract][Full Text] [Related]
25. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.
Saxena S; Winograd A; Dunkin JJ; Maidment K; Rosen R; Vapnik T; Tarlow G; Bystritsky A
J Clin Psychiatry; 2001 Jan; 62(1):67-72; quiz 73. PubMed ID: 11235937
[TBL] [Abstract][Full Text] [Related]
26. Donepezil as Add-on Treatment for Resistant Obsessive-Compulsive Disorder: Retrospective Case Series.
Bergman J; Miodownik C; Lerner PP; Miodownik E; Shulkin A; Lerner V
Clin Neuropharmacol; 2016; 39(4):194-6. PubMed ID: 27223667
[TBL] [Abstract][Full Text] [Related]
27. Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series.
Miodownik C; Bergman J; Lerner PP; Kreinin A; Lerner V
Clin Neuropharmacol; 2015; 38(1):26-9. PubMed ID: 25580923
[TBL] [Abstract][Full Text] [Related]
28. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
29. Severe obsessive-compulsive disorder with and without comorbid hair pulling: comparisons and clinical implications.
Stewart SE; Jenike MA; Keuthen NJ
J Clin Psychiatry; 2005 Jul; 66(7):864-9. PubMed ID: 16013902
[TBL] [Abstract][Full Text] [Related]
30. [Combination of ketamine and esketamine with Exposure and Response Prevention (ERP) therapy for Obsessive-Compulsive Disorder].
Bottemanne H; Arnould A; Najar A; Delaigue F; Serresse L; Joly L; Mouchabac S
Encephale; 2023 Jun; 49(3):304-311. PubMed ID: 37095049
[TBL] [Abstract][Full Text] [Related]
31. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F
Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176
[TBL] [Abstract][Full Text] [Related]
32. Deep brain stimulation for obsessive-compulsive disorder: A systematic review of worldwide experience after 20 years.
Mar-Barrutia L; Real E; Segalás C; Bertolín S; Menchón JM; Alonso P
World J Psychiatry; 2021 Sep; 11(9):659-680. PubMed ID: 34631467
[TBL] [Abstract][Full Text] [Related]
33. Clinical case report: considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy.
Kaltenboeck A; Foerster E; Strafner S; Demal U; Mossaheb N; Friedrich F
Front Psychiatry; 2023; 14():1291077. PubMed ID: 38090708
[TBL] [Abstract][Full Text] [Related]
34. Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder.
Di Salvo G; Maina G; Pessina E; Teobaldi E; Barbaro F; Martini A; Albert U; Rosso G
Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374357
[No Abstract] [Full Text] [Related]
35. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
36. The relation between depressive and obsessive-compulsive symptoms in obsessive-compulsive disorder: Results from a large, naturalistic follow-up study.
Rickelt J; Viechtbauer W; Lieverse R; Overbeek T; van Balkom AJ; van Oppen P; van den Heuvel OA; Marcelis M; Eikelenboom M; Tibi L; Schruers KR
J Affect Disord; 2016 Oct; 203():241-247. PubMed ID: 27310102
[TBL] [Abstract][Full Text] [Related]
37. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G
Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
39. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
[TBL] [Abstract][Full Text] [Related]
40. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
